NovaBridge Biosciences NBP
0.88 USD -0.02 (-2.58%)
Regular-session close
0.90 +0.02 +2.30%
After hours · Nov 19, 5:40 PM ET
0.85 Day range 0.9033
0.751 52-week range 5.19
- YTD
- -77.89%
- 1 year
- -80.58%
5D +0.0441 (+5.13%)
- Market cap
- 102.06M
- EPS (ttm)
- -0.69
- YTD return
- -77.89%
- 1-year return
- -80.58%
- Volume
- 213.66K
- Avg volume
- 509.77K
- Open
- 0.9033
- Previous close
- 0.9031
- Day's range
- 0.85 – 0.9033
- 52-week range
- 0.751 – 5.19
Fundamental scorecard
4 of 25 checks passed on NBP’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
NBP Revenue — quarterly 0
NBP Net income — quarterly -30.79M
NBP EPS — quarterly -0.299
News
NovaBridge’s Subsidiary Visara Doses First Patient In ASCEND Study, Randomized Phase 2b Trial To Evaluate VIS-101 In Patients With Wet Age-Related Macular Degeneration
Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia
Your note
Sign in to keep a note on NBP — it syncs with the Stock Master app.
